ES2880813T3 - Formulaciones farmacéuticas de naproxeno para encapsulación en gel blando y combinaciones de las mismas - Google Patents

Formulaciones farmacéuticas de naproxeno para encapsulación en gel blando y combinaciones de las mismas Download PDF

Info

Publication number
ES2880813T3
ES2880813T3 ES11734283T ES11734283T ES2880813T3 ES 2880813 T3 ES2880813 T3 ES 2880813T3 ES 11734283 T ES11734283 T ES 11734283T ES 11734283 T ES11734283 T ES 11734283T ES 2880813 T3 ES2880813 T3 ES 2880813T3
Authority
ES
Spain
Prior art keywords
naproxen
weight
amount
formulation
ranges
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES11734283T
Other languages
English (en)
Spanish (es)
Inventor
John Lopez
Peter Draper
Sankalp Vashishtha
Nancy Klassen
Christina Armstrong
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Catalent Ontario Ltd
Original Assignee
Catalent Ontario Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Catalent Ontario Ltd filed Critical Catalent Ontario Ltd
Application granted granted Critical
Publication of ES2880813T3 publication Critical patent/ES2880813T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/192Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4833Encapsulating processes; Filling of capsules
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4858Organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4866Organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ES11734283T 2010-01-19 2011-01-19 Formulaciones farmacéuticas de naproxeno para encapsulación en gel blando y combinaciones de las mismas Active ES2880813T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CA2690488A CA2690488C (en) 2010-01-19 2010-01-19 Pharmaceutical formulations of naproxen for soft gel encapsulation and combinations thereof
PCT/CA2011/000059 WO2011088553A1 (en) 2010-01-19 2011-01-19 Pharmaceutical formulations of naproxen for soft gel encapsulation and combinations thereof

Publications (1)

Publication Number Publication Date
ES2880813T3 true ES2880813T3 (es) 2021-11-25

Family

ID=44303618

Family Applications (1)

Application Number Title Priority Date Filing Date
ES11734283T Active ES2880813T3 (es) 2010-01-19 2011-01-19 Formulaciones farmacéuticas de naproxeno para encapsulación en gel blando y combinaciones de las mismas

Country Status (13)

Country Link
US (4) US9480667B2 (https=)
EP (2) EP2525789B1 (https=)
JP (2) JP5975884B2 (https=)
AU (1) AU2011207061B2 (https=)
CA (1) CA2690488C (https=)
DK (1) DK2525789T3 (https=)
ES (1) ES2880813T3 (https=)
HU (1) HUE055771T2 (https=)
MX (1) MX358636B (https=)
PL (1) PL2525789T3 (https=)
PT (1) PT2525789T (https=)
SI (1) SI2525789T1 (https=)
WO (1) WO2011088553A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201301626D0 (en) 2013-01-30 2013-03-13 Dignity Sciences Ltd Composition comprising 15-OHEPA and methods of using the same
US9682055B2 (en) 2014-06-04 2017-06-20 Dignity Sciences Limted Pharmaceutical compositions comprising DGLA and use of same
CN104083339A (zh) * 2014-08-04 2014-10-08 人福普克药业(武汉)有限公司 萘普生钠软胶囊及其制备方法
US10368284B2 (en) * 2014-11-12 2019-07-30 T-Mobile Usa, Inc. Quality of experience-based handover management
MA47141A (fr) 2015-05-13 2019-11-06 Ds Biopharma Ltd Compositions comprenant du15-oxo-epa ou du 15-oxo-dgla et leurs procédés de préparation et d'utilisation
ES2851525T3 (es) 2015-07-21 2021-09-07 Afimmune Ltd Composiciones que comprenden 15(S)-HEPE para su uso en la sensibilización de las células cancerosas a la radioterapia
CA3129008A1 (en) 2015-12-18 2017-06-22 Afimmune Limited Compositions comprising 15-hepe and methods of using the same
CA3100314A1 (en) 2018-05-16 2019-11-21 Bayer Healthcare Llc High concentration suspension formulation for cold and flu soft gel capsule medications
CN109692127A (zh) * 2019-03-15 2019-04-30 王征 一种密封小胶囊的制备方法
BR112021021414A2 (pt) * 2019-04-26 2022-02-15 Scherer Technologies Llc R P Composição do mini softgel de naproxeno
US20210315851A1 (en) 2020-04-03 2021-10-14 Afimmune Limited Compositions comprising 15-hepe and methods of treating or preventing hematologic disorders, and/or related diseases
US20220233452A1 (en) * 2021-01-25 2022-07-28 R.P. Scherer Technologies, Llc Mini softgel naproxen composition

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA821577B (en) 1981-04-06 1983-03-30 Boots Co Plc Therapeutic agents
US4443428A (en) * 1982-06-21 1984-04-17 Euroceltique, S.A. Extended action controlled release compositions
US5071643A (en) 1986-10-17 1991-12-10 R. P. Scherer Corporation Solvent system enhancing the solubility of pharmaceuticals for encapsulation
US5073371A (en) 1990-11-30 1991-12-17 Richardson-Vicks, Inc. Leave-on facial emulsion compositions
WO1995007103A1 (en) * 1993-09-07 1995-03-16 The Procter & Gamble Company Compositions containing an amino acid salt of propionic acid non-steroidal anti-inflammatory agent and at least one of a decongestant, an expectorant, an antihistamine and an antitussive
MX9602955A (es) * 1994-01-24 1997-06-28 Procter & Gamble Procedimiento para solubizar activos farmaceuticos dificilmente solubles.
US5484606A (en) * 1994-01-24 1996-01-16 The Procter & Gamble Company Process for reducing the precipitation of difficulty soluble pharmaceutical actives
US5641512A (en) * 1995-03-29 1997-06-24 The Procter & Gamble Company Soft gelatin capsule compositions
ATE429210T1 (de) * 1998-01-20 2009-05-15 Applied Analytical Ind Inc Orale flüssige zusammensetzungen
US6383515B2 (en) * 1999-05-28 2002-05-07 Sawyer Maryjean Solvent system for enhancing solubility
US6387400B1 (en) 2000-08-29 2002-05-14 R.P. Scherer Technologies, Inc. Process for preparing pharmaceutical compositions for use with soft gelatin formulations
US20090318558A1 (en) * 2003-02-12 2009-12-24 Jae-Hwan Kim Solvent system of hardly soluble drug with improved dissolution rate
EP1605916A4 (en) * 2003-02-12 2012-02-22 R & P Korea Co Ltd SOLVENT SYSTEM OF A SMOOTH MEDICAMENT WITH IMPROVED ELUTION RATE
US20070053868A1 (en) 2005-03-08 2007-03-08 Banner Pharmacaps, Inc. Solvent system for enhancing the solubility of pharmaceutical agents
US7582679B2 (en) * 2006-02-03 2009-09-01 Pharmaceutics International Incorporated Compositions containing solid ibuprofen concentrates and methods of making solid ibuprofen concentrates
US20080014274A1 (en) * 2006-07-14 2008-01-17 Wyeth Enhanced stability phenylephrine liquid compositions
US20110052679A1 (en) * 2009-08-25 2011-03-03 Pharmaceutics International, Inc. Solid naproxen concentrates and related dosage forms

Also Published As

Publication number Publication date
US20200046662A1 (en) 2020-02-13
MX358636B (es) 2018-08-29
JP2013517304A (ja) 2013-05-16
US20130011470A1 (en) 2013-01-10
EP2525789B1 (en) 2021-06-02
EP2525789A1 (en) 2012-11-28
US12605348B2 (en) 2026-04-21
PT2525789T (pt) 2021-07-19
MX2012008300A (es) 2012-11-23
US20170020832A1 (en) 2017-01-26
WO2011088553A1 (en) 2011-07-28
CA2690488A1 (en) 2011-07-19
EP2525789A4 (en) 2014-04-30
CA2690488C (en) 2013-06-11
EP3909567B1 (en) 2026-04-29
HUE055771T2 (hu) 2021-12-28
US10463637B2 (en) 2019-11-05
PL2525789T3 (pl) 2022-01-03
SI2525789T1 (sl) 2021-12-31
US9480667B2 (en) 2016-11-01
AU2011207061A1 (en) 2012-07-26
US11896566B2 (en) 2024-02-13
DK2525789T3 (da) 2021-07-19
JP2016094462A (ja) 2016-05-26
EP3909567A1 (en) 2021-11-17
AU2011207061B2 (en) 2015-05-28
US20240139132A1 (en) 2024-05-02
JP5975884B2 (ja) 2016-08-23

Similar Documents

Publication Publication Date Title
ES2880813T3 (es) Formulaciones farmacéuticas de naproxeno para encapsulación en gel blando y combinaciones de las mismas
ES2603225T3 (es) Sistema de cápsulas blandas sin gelatina
ES2792082T3 (es) Estabilidad mejorada de composiciones líquidas novedosas
ES2556217T3 (es) Formulación en bolsa para polímeros de amina
US20030232097A1 (en) Oily wax matrix suspension formulation comprising ibuprofen free acid and potassium salt of ibuprofen
WO2009066146A2 (en) Stable solutions of sparingly soluble actives
ES2424492T3 (es) Composición pulverulenta o granulada que comprende un copolímero, una sal de un ácido monocarboxílico graso y un ácido monocarboxílico graso y/o un alcohol graso
JP2009197015A (ja) ハードシェルカプセル剤のためのイブプロフェン溶液
ES2641889T3 (es) Formulaciones de diclofenaco y métodos de uso
WO2008070950A1 (en) Pharmaceutical solution formulations for encapsulation into gelatin capsules or other dosage forms
WO2005046727A2 (en) Ibuprofen-containing soft gelatin capsules
JP4394447B2 (ja) アセトアミノフェン組成物
WO2016084099A1 (en) Soft gelatin capsule composition of anti-tussive agents
ES2488191T3 (es) Composición farmacéutica que contiene un extracto de Serenoa repens
ES2316308A1 (es) Medicamente a base de metronidazol y acido azelaico para el tratamiento por via topica de la enfermedad rosacea de mejor asimilacion, y procedimiento de preparacion.